ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

GSK Gsk Plc

1,653.00
12.50 (0.76%)
26 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Gsk Plc LSE:GSK London Ordinary Share GB00BN7SWP63 ORD 31 1/4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  12.50 0.76% 1,653.00 1,654.00 1,655.00 1,655.50 1,634.00 1,638.50 3,990,601 16:35:15
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 30.33B 4.93B 1.1970 13.83 68.14B
Gsk Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker GSK. The last closing price for Gsk was 1,640.50p. Over the last year, Gsk shares have traded in a share price range of 1,302.60p to 1,719.80p.

Gsk currently has 4,117,033,438 shares in issue. The market capitalisation of Gsk is £68.14 billion. Gsk has a price to earnings ratio (PE ratio) of 13.83.

Gsk Share Discussion Threads

Showing 17176 to 17199 of 33100 messages
Chat Pages: Latest  688  687  686  685  684  683  682  681  680  679  678  677  Older
DateSubjectAuthorDiscuss
29/3/2018
11:39
The judge in the latest Teva ruling appears to have a less-than-squeaky clean record of disclosure, according to this:



One wonders whether he holds shares in the Israeli firm or other conflict of interest?

tradermichael
29/3/2018
11:27
Among UK-listed pharmaceutical firms, GlaxoSmithKline (GSK) – which has a wide moat and a four-star rating – faces low exposure to US drug policy changes and represents one of the most undervalued firms in the drug area. Likewise, the majority of AstraZeneca’s (AZN) sales are derived outside the US, so the wide-moat firm faces fewer repercussions from changes to drug pricing there. But Shire (SHP), which could be the subject of a takeover bid from Japan’s Takeda, could see 2019 earnings hit by exposure to the medical benefits coverage market.
fangorn2
29/3/2018
11:20
- As for the Teva case, its demonstrates that "the law is an ass......"

Does seem so doesn't it - the judge upheld that Teva had infringed the patent but according to him apparently this doesn't matter. This kind of ruling, along with moves on biosimilars threatens to disincentive the kind of risk taking that can lead to some of the most cutting edge treatments.

- Its not a concern.

Totally agree, their debt level is completely sustainable and in any case they have the means to substantially reduce it relatively quickly if they ever wanted to. As it is they reduced debt by over 1Bn last year. They also generate more free cash flow than suggested by the conservatively calculated figure they reported in their results.

romeike
29/3/2018
09:23
Its not a concern.

The extra part from Novartis bolts on to an earnings accretive deal. Overall annual sales are topping £30 billion and growing ..... analysts predict Shingrix will reach sales of $1.368 billion by 2020

tradermichael
29/3/2018
09:14
I hope this goes up just concerned about the debt levels
mj19
29/3/2018
08:15
As for the Teva case, its demonstrates that "the law is an ass......"
tradermichael
29/3/2018
02:43
Mixed emotions glad it's going up, gutted if I don't get my reinvestment dividends at a good price, lol
montyhedge
28/3/2018
22:31
Yeah hardly a game changer, onwards to 1570p next quarter
ny boy
28/3/2018
21:55
I dont think shares plunged. I looks like the shares are up in NY
Up 2.5% and another .9% after hours ?

235m is about 4p on the share so of zilch significance.

amt
28/3/2018
21:05
OopsGlaxoSmithKline shares plunge on drug verdict
watfordhornet
28/3/2018
19:52
That's an error on Google. Happens now and then check GSK ADR. Unfortunately Google Finance is pretty much useless now after 'improvements' , which seems to be a recurring theme with Google stuff.
romeike
28/3/2018
19:04
Glaxo (GSK) To Acquire Novartis (NVS) Consumer Healthcare Business Stake For $13B - Slideshow
fangorn2
28/3/2018
18:58
Where did 1179.39 come from?
igerald
28/3/2018
18:54
Pardon me if this is a silly question but:where did 1179.39 come from?
igerald
28/3/2018
18:54
Pardon me if this is a silly question but:where did 1179.39 come from?
igerald
28/3/2018
18:03
no i ll buy some p v r instead
billionaire1
28/3/2018
17:49
Buy beaten up Vodafone !
abdullla
28/3/2018
17:23
only down side is we wont get as many shares for our divi reinvest
billionaire1
28/3/2018
17:16
Nudging £14 on close, that'll do me :-)
losos
28/3/2018
17:04
imastu pidgitaswell
28 Mar '18 - 09:03 - 17155 of 17170 Edit
0 1 0
Might also take a while to get through 1360-70, the wider market notwithstanding

Or maybe not. What does he know, muppet:


free stock charts from uk.advfn.com

imastu pidgitaswell
28/3/2018
16:46
Breakout underway on stronger volumes, bidders ready to take out the Horlicks brand, strong sector with bid speculation mounting for Shire today.

Looking forward a a nice juicy GSK quarterly divi payout on 12 April

ny boy
28/3/2018
15:34
In theory no reason not to go back to 1550p.
montyhedge
28/3/2018
15:28
Thats yesterdays high taken out,nice.
tim 3
28/3/2018
15:20
All coming out of the woodwork (LOL)TraderMichael Buy to 1950 unchanged
tradermichael
Chat Pages: Latest  688  687  686  685  684  683  682  681  680  679  678  677  Older

Your Recent History

Delayed Upgrade Clock